Beta
Ethosuximide
medication Under reviewAn antiepileptic medication primarily used to treat absence (petit mal) seizures.
Research summary
Ethosuximide demonstrates significant efficacy in treating absence epilepsy, with seizure freedom rates of approximately 53% in initial monotherapy treatment. Recent precision dosing research indicates that higher initial doses (40-55 mg/kg daily) may improve outcomes, with 75% probability of seizure freedom at the higher dose. The medication shows comparable efficacy to valproic acid but with better tolerability. Research in animal models suggests ethosuximide may have anti-epileptogenic properties, potentially preventing disease progression when administered early. Clinical trials are currently investigating its potential use for neuropathic pain management.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Generalized anxiety disorder or anxiety symptoms affecting daily life
Ethosuximide-treatment-inhibits-epileptogenesis-and-alleviates-behavioural-co-morbidities-in-the-GAERS-model-of-absence-epilepsy
Not specified
Research (1 study)
Ethosuximide-treatment-inhibits-epileptogenesis-and-alleviates-behavioural-co-morbidities-in-the-GAERS-model-of-absence-epilepsy
Not specified
Community updates
No updates yet for this supplement.
Be the first to share your experience!